Drug interactions
Larotrectinib + Linagliptin-metformin
Severity: Minor
Larotrectinib and Linagliptin-metformin: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Larotrectinib is a CYP3A4 substrate and a modest inhibitor of CYP3A4 in vitro, which could raise exposure to linagliptin. Linagliptin has a wide safety margin and is mainly eliminated unchanged, so a meaningful effect is unlikely.
What this interaction means in plain words
Larotrectinib and Linagliptin-metformin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Larotrectinib belongs to Oncology; Linagliptin-metformin belongs to Endocrine.
Why it happens
Possible weak inhibition of CYP3A4 and P-glycoprotein-mediated handling of linagliptin.
What to do
No dose change is usually needed. Monitor glucose control and for hypoglycemia, especially if a sulfonylurea or insulin is also used.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Larotrectinib and Linagliptin-metformin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Linagliptin-metformin
Other interactions of Larotrectinib
Frequently asked questions
Can I take Larotrectinib with Linagliptin-metformin?
MediHelp rates the interaction as minor. Larotrectinib and Linagliptin-metformin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Larotrectinib is a CYP3A4 substrate and a modest inhibitor of CYP3A4 in vitro, which could raise exposure to linagliptin. Linagliptin has a wide safety margin and is mainly eliminated unchanged, so a meaningful effect is unlikely.
How serious is the interaction between Larotrectinib and Linagliptin-metformin?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No dose change is usually needed. Monitor glucose control and for hypoglycemia, especially if a sulfonylurea or insulin is also used.
What other medicines interact with Linagliptin-metformin?
MediHelp also lists interactions of Linagliptin-metformin with, for example, Apalutamide, Carbamazepine, Contrast media. The full list is on the Linagliptin-metformin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
